A patient with heavily pretreated relapsed/refractory diffuse large B-cell lymphoma achieved complete remission following ...

Genocury Biotech announces positive results from noval in vivo CD19 CAR-T therapy in relapsed/refractory diffuse large B-cell lymphoma: Shenzhen, China Friday, May 2, 2025, 15:00 ...

This study presents a valuable finding on the direct cytotoxic effects of DuoHexaBody-CD37 in diffuse large B-cell lymphoma, mediated via SHP-1 activation and antibody clustering, independent of ...

Diffuse large B-cell lymphoma (DLBCL) is the most common and fast-growing type of non-Hodgkin lymphoma, a cancer that affects ...

Disclaimer: AlphaGalileo is not responsible for the accuracy of content posted to AlphaGalileo by contributing institutions ...

Mr. Zhou, a 63-year-old resident of Shanghai, returned to a hospital for what would become his third fight against diffuse ...

Approval based on Phase III STARGLO study where Columvi in combination with chemotherapy showed a 41% reduction in the risk ...

BLINK-182 frontman Mark Hoppus has revealed he genuinely believed he was going to die after being diagnosed with a ...

Thousands of regional Queenslanders will have better access to lifesaving treatment, with a lymphoma medication listed on the ...

During a live event, Caron A. Jacobson, MD, MMSc, and participants discussed how they decide on therapy for patients with relapsed/refractory diffuse large B-cell lymphoma.